Allergan, Inc. v. Sandoz, Inc. et al, No. 2:12-cv-00207 (E.D. Tex. Mar. 29, 2016)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Before the Court are Plaintiff Allergan Sales, LLC’s (“Allergan”) Opening Claim Construction Brief (Dkt. No. 232), Sandoz, Inc., Alcon Laboratories, Inc., Alcon Research, Ltd., and Falcon Pharmaceuticals, Ltd.’s ( collectively, “Sandoz”) Respons ive Claim Construction Brief (Dkt. No. 235), and Allergan’s Reply Claim Construction Brief (Dkt. No. 238). The Court held a hearing on March 2, 2016, to determine the proper construction of the disputed terms in this case.